Mobile

A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to p...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011200-39

A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the clinical antidepressant effects of GW856553 versus placebo treatment at Week 6 in adult subjects diagnosed with MDD with symptoms of decreased energy and interest, and with psychomotor retardation.

Critère d'inclusion

  • Major Depressive Disorder

Liens